Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Zoledronic Acid for Osteoporosis in Children
NCT02632916Phase 2Completed
- Sponsor
- Children's Hospital of Eastern Ontario
- Start
- Aug 2016
- Primary completion
- Feb 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of denosumab in osteoporosis (2 arms), sponsored by Children's Hospital of Eastern Ontario. Primary endpoint: Changes in serum ionized calcium levels. Started Aug 2016; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02632916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632916.